Finzati - Logo
ADAP logo

Adaptimmune Therapeutics plc

ADAP • Biotechnology
Strong market move
ADAP+19.38%
vs. previous close $0.05
$0.06
▲ +0.01 (+19.38%)
Current price
EarningsLatest report: Jun 30, 2025
HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$15.29M
Growth
—
Cash Flow
1/5
Trend
Volatile
Evidence
Positive revenue growth · 124.5%Healthy liquidity · 2.92High debt level · 6.26Weak profitability
Financial data as of: Jun 30, 2025, 12:00 AM UTCLast earnings update: Aug 13, 2025, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.06
Change19.38%
Shares Out264.09M
Market Cap$15.29M
Enterprise Value$19.42M
52W Range0.02 - 0.86
Beta2.49
P/E-0.09
P/S0.23
P/B-0.22
P/FCF-0.08
EV/Sales0.30

Investment DNA

How strong this company looks for long-term investors

49
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
58/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
58/100
Why this score▼
Positive revenue growth · 124.5%Healthy liquidity · 2.92High debt level · 6.26Weak profitability

Analyst view

Analyst sentiment and price target

ADAP
Analyst sentiment
Based on 16 analyst votes · 2026-10-20
69/100
Neutral
Bullish
9
Hold
4
Bearish
3
Price Target
2026-06-06
Low
$1.00
Mean
$2.83
Median
$3.00
High
$4.00

Company Overview

IPO: 5/6/2015
Industry: Biotechnology
P/B i: -0.22
Debt / Equity i: 6.26
Operating Margin: -38.62%
Net Margin: -39.78%
ROE i: -
ROIC: -

Financial Health

Score12 / 20
Debt / Equity: 6.26
Current Ratio: 2.92
Quick Ratio: 2.80
Status: Good

Warnings

  • High debt level
🧾

No insider activity

No recent insider transactions available.